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The Ubiquitin Proteasome System (UPS) is a major actor of muscle wasting during various
physio-pathological situations. In the past 15 years, increasing amounts of data have
depicted a picture, although incomplete, of the mechanisms implicated in myofibrillar
protein degradation, from the discovery of muscle-specific E3 ligases to the identification
of the signaling pathways involved. The targeting specificity of the UPS relies on the
capacity of the system to first recognize and then label the proteins to be degraded
with a poly-ubiquitin (Ub) chain. It is fairly assumed that the recognition of the substrate
is accomplished by the numerous E3 ligases present in mammalian cells. However,
most E3s do not possess any catalytic activity and E2 enzymes may be more than
simple Ub-providers for E3s since they are probably important actors in the ubiquitination
machinery. Surprisingly, most authors have tried to characterize E3 substrates, but the
exact role of E2s in muscle protein degradation is largely unknown. A very limited number
of the 35 E2s described in humans have been studied in muscle protein breakdown
experiments and the vast majority of studies were only descriptive. We review here the
role of E2 enzymes in skeletal muscle and the difficulties linked to their study and provide
future directions for the identification of muscle E2s responsible for the ubiquitination of
contractile proteins.
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INTRODUCTION
Skeletal muscle atrophy is a common adaptation of the organ-
ism during disuse (denervation, unloading) and various diseases
(cancer, sepsis, diabetes, kidney failure, etc.). Compelling data
demonstrated that an increased proteolysis is the main factor
explaining muscle wasting (Attaix et al., 2005), and several studies
suggest that the ubiquitin proteasome system (UPS) is respon-
sible for most of this adaptation, including in humans (Polge
et al., 2011). Amongst the overall myofibrillar proteins, actin and
myosin heavy chains (in atrophying skeletal muscle) and troponin
I (in cardiomyocytes) were confirmed to be UPS substrates (Kedar
et al., 2004; Clarke et al., 2007; Fielitz et al., 2007; Heng et al., 2008;
Polge et al., 2011). Other potential substrates of the UPS during
muscle atrophy include other members of the troponin family,
myosin light chains and telethonin (Kedar et al., 2004; Heng et al.,
2008; Cohen et al., 2009).
In parallel, most efforts were put on deciphering the mecha-
nisms by which myofibrillar proteins are targeted and degraded
by the UPS. Covalent modification of proteins by ubiquitin (Ub)
is a highly sophisticated and polyvalent signal as Ub linked to
substrate can be monomeric, attached in chains using any of
the seven internal Ub lysines or even combined with other Ub-
like modifiers (Ravid and Hochstrasser, 2008; Kravtsova-Ivantsiv
and Ciechanover, 2012; Ciechanover and Stanhill, 2014).Whereas
several Ub modifications (e.g., K63 chains) lead to proteasome-
independent degradation or non-proteolytic fate for the target
(Panier and Durocher, 2009; Wertz and Dixit, 2010; Sandri,
2013), proteins carrying Ub chains linked through K48 (or some-
times K11) are bona fide substrates for the 26S proteasome. The
latter recognizes these Ub chains as a degradation signal, trims
the Ub moieties and degrades the target proteins into small pep-
tides. The whole process is highly specific and tightly regulated
in response to catabolic stimuli to avoid unwanted degradation
of proteins. The first steps of the UPS are dedicated to substrate
recognition and thus represent a crucial point for controlling
substrate fate together with a potential entry for developing ther-
apeutical strategies. Ubiquitination of substrates involves several
hundreds of enzymes distributed in three classes that act in cas-
cade (Polge et al., 2013). Ub is first activated by a single E1 (Ub
activating enzyme) that transfers high energy Ub to one of the 35
E2s (Ub conjugating enzymes) (Van Wijk and Timmers, 2010).
The E2s transfer Ub on target proteins in conjunction with the
third class of enzymes, namely E3 ligases (>600, Metzger et al.,
2012). An E2 is able to cooperate with different E3s and vice
versa, which enables the specific targeting of virtually any cellu-
lar protein. E3s recognize the target protein to be degraded and
thus bring specificity to the ubiquitination machinery but most
E3s lack enzymatic activity so that the E2-E3 couple is func-
tionally more relevant. Different E3 ligases have been implicated
in muscle development and/or atrophy. For example, MuRF1
is a muscle-specific E3 ligase regulated in nearly any catabolic
situation by different transcription mediators like FoxOs (see
Bodine and Baehr, 2014 for a recent review). Interestingly,MuRF1
(and perhaps the MuRF3 isoform) is able to target the major
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myofibrillar proteins for subsequent degradation by the 26S pro-
teasome (Kedar et al., 2004; Clarke et al., 2007; Fielitz et al., 2007;
Polge et al., 2011). However, a yet unanswered question is about
the identity of the E2s that work in pairs with MuRF1. Indeed,
MuRF1 belongs to the RING finger E3 ligase family (the most
numerous) that does not possess any catalytic activity and relies
on E2 enzymes for targeting the proteins to be degraded. Other
RING (Really Interesting New Genes) E3 ligases like Trim32 or
TRAF6 may have a role in the atrophying program and also
need specific E2s for correctly targeting substrates for degrada-
tion (Kudryashova et al., 2005; Hishiya et al., 2006; Kumar et al.,
2012). E2 enzymes determine the type of chain built on the sub-
strate and thus whether the ubiquitination of the target protein
is dedicated to degradation or to other fates (signaling, modula-
tion of activity, etc.). In addition, E2s bound to their cognate E3
are positioned in such a way that the residues ubiquitinated in
the substrate are specifically chosen (David et al., 2010; Van Wijk
and Timmers, 2010; Napolitano et al., 2011). Thus, E2s are cen-
tral players in the ubiquitination machinery but the exact role of
E2s in the development of skeletal muscle atrophy is still an open
question.
Thirty-five E2s (plus 2 putative) are described in the human
genome and have been grouped in 4 different classes (Van
Wijk and Timmers, 2010). Class I only possesses the catalytic
core/Ubiquitin Conjugating (Ubc fold) domain, class II and III
have N- or C-terminal extensions respectively and class IV pos-
sesses both. Classification of E2s is still debated as they are
grouped in 17–18 families depending on authors (Jones et al.,
2002; Michelle et al., 2009). For easiest comprehension we will
refer in this manuscript to the current nomenclature (UBE2x)
with x defining each individual E2 enzyme. An intriguing feature
is the presence of highly similar isoforms in some E2 families. For
example, UBE2A and UBE2B share 96% homology at the pro-
tein level (Adegoke et al., 2002), raising an important question:
do they have redundant functions? While pioneering experiments
tended to globally attribute roles to the whole family, more recent
data may modify this point of view. Indeed, our knowledge on
the role of E2s during skeletal muscle atrophy relies almost exclu-
sively on descriptive observations (mRNA levels) or on in vitro
ubiquitination assays. The former are not really informative about
mechanisms and specific features of E2s may bias the latter. We
will discuss in this review our knowledge about E2s in skeletal
muscle and focus more deeply on the two families that gather
most data, including their potential link with one of the most
important E3 during muscle atrophy (MuRF1). We will then
address the particular features and pitfalls that have impeded to
clearly depict the roles of E2 enzymes in atrophying muscles and
future direction that should be developed for better deciphering
UPS roles.
UBE2 ENZYMES AND MUSCLE ATROPHY
THE ROLE OF THE UBE2B FAMILY IN MUSCLE ATROPHY: THE
EVERLASTING QUESTION?
Expression levels
Two class I members are present in this family, UBE2A/HR6A
and UBE2B/14-kDa E2/HR6B (also referred as E2-17 kDa in
humans), the latter being the most studied/tested E2 enzyme in
skeletal muscle so far. These two members were among the first
identified E2 enzymes, are present in different organs and share
high identity both at the mRNA (80%) and protein (96%) levels
in mammals (Koken et al., 1991; Adegoke et al., 2002). Although
predominant in testis, pioneering work by Simon Wing’s labora-
tory found that UBE2B is abundant in skeletal muscle and regu-
lated upon fasting and by insulin (Wing and Banville, 1994; Wing
and Bedard, 1996; Adegoke et al., 2002). One particular feature
of UBE2B is that two mRNAs are present in mammals (1.2 and
1.8 kb), the smaller one being particularly sensitive to catabolic
situations. Since this early work, different laboratories, including
ours, found that UBE2B mRNA levels are up-regulated in nearly
any catabolic situation (summarized in Table 1). These data com-
prise different models and muscles, from human to flies and from
phasic to anti-gravity muscles. In addition, UBE2B expression is
also well correlated to the expression of 26S proteasome subunits
in atrophying muscles. It should be emphasized that the system-
atic recruitment of UBE2B is skeletal muscle-specific, as UBE2B
is not modified in atrophying or hypertrophying heart (Razeghi
et al., 2006). In summary, UBE2B mRNA levels are tightly linked
to muscle wasting whatever the catabolic stimuli is, which sug-
gests major roles of UBE2B downstream a ubiquitous atrophying
program and that UBE2B targets are common to many catabolic
states.
If a proteolytic enzyme is implicated in the systematic degra-
dation of skeletal muscle proteins in atrophying conditions, we
could expect this enzyme being also down-regulated during
recovery processes and/or when anabolic stimuli are delivered to
skeletal muscle. Accordingly, using a non-pathological atrophy-
ing model (unweighting), we found that UBE2B was among the
first enzymes down regulated after reloading of animals. Actually,
UBE2B mRNA levels are severely repressed from +342% during
the atrophying phase to −68% as soon as 18 h after reloading,
which is much more sensitive than any of the UPS compo-
nents tested (Taillandier et al., 1996, 2003). Interestingly, UBE2B
mRNA is controlled by anabolic factors, as both insulin and IGF-
1 lower UBE2B mRNA levels in cultured L6 myotubes but by
a different mechanism. While insulin lowers UBE2B mRNAs by
playing on transcription, IGF-1 has a direct effect on UBE2B
mRNA stability and increases its degradation (Wing and Banville,
1994; Wing and Bedard, 1996). The impact of IGF-1 on UBE2B
mRNA was also observed in rats treated with dexamethasone
(Dex) and in septic animals (Dardevet et al., 1995; Chrysis and
Underwood, 1999; Fang et al., 2000). However, depressing UBE2B
mRNA and other components of the UPS had only a limited
impact on muscle mass when catabolic stimuli were present and
this absence of a clear effect might reflect compensatory mecha-
nisms, e.g., an adjustment of the protein synthesis/degradation
balance. Muscle mass is submitted to daily variations due to
the alternation of postabsorptive (catabolic) and postprandial
(anabolic) phases, which is a physiological mechanism regulat-
ing protein homeostasis. Aging is characterized by the loss of the
postprandial inhibition of proteolysis, in which different compo-
nents of the UPS are normally upregulated, including UBE2B.
Interestingly, leucine supplementation restores the postprandial
inhibition of proteolysis by decreasing UBE2B and other UPS
mRNA levels (Combaret et al., 2005). In vitro experiments using
C2C12 myotubes suggested that the leucine effect was mediated
by insulin (Sadiq et al., 2007).
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Table 1 | Variation of UBE2B mRNA levels in anabolic and catabolic situations.
UBE2B Conditions References
ANABOLIC SITUATIONS
↘ Insulin, IGF-1 Wing and Banville, 1994; Wing and Bedard, 1996
CATABOLIC SITUATIONS
Non pathological states ↗ Fasting Wing and Banville, 1994; Adegoke et al., 2002; Kee et al., 2003
Vitamin D deficiency Bhat et al., 2013
Immobilization / unweighting Taillandier et al., 1996; Yimlamai et al., 2005
Aging Combaret et al., 2005
Burn injury Fang et al., 2000; Chai et al., 2002
Head trauma Mansoor et al., 1996
Pathological and injury states ↗ Hyperthermia Smith et al., 2005
Mechanical ventilation Mcclung et al., 2008
Glucocorticoid treatment Dardevet et al., 1995; Chrysis and Underwood, 1999
Diabetes Lecker et al., 1999
Cancer Lorite et al., 1998; Combaret et al., 2002; Khal et al., 2005;
Mackenzie et al., 2005
Sepsis Voisin et al., 1996; Fang et al., 2000; Fischer et al., 2000
Biliary cirrhosis Lin et al., 2005
Programmed cell death of skeletal muscle Haas et al., 1995
Increased ROS levels Li et al., 2003
UBE2B mRNA levels were depressed upon insulin or IGF-1 treatment.
UBE2B was upregulated at the mRNA level in any of the mentioned catabolic situations.
Expression at the mRNA levels may not be sufficient for prov-
ing that UBE2B is important for muscle homeostasis. However,
few studies confirmed a role for UBE2B at the protein level
partly because most antibodies cross-react with the isoform
UBE2A. In rats submitted to unweighting atrophy, we found
that increased UBE2B mRNA levels correlated with efficient
translation (Taillandier et al., 1996). Using a moderate catabolic
model (fasting), other authors found that UBE2B protein levels
were not modified while mRNA levels were elevated (Adegoke
et al., 2002). These authors concluded that increased mRNA
levels were probably required for maintaining enzyme levels,
which is suggestive of a posttranscriptional regulation. The
simplest explanation is that UBE2B turnover is dramatically
increased in atrophying muscle even though this remains to be
established.
Ubiquitination activity: E3 partners and substrates
Different UBE2B ubiquitinating activities were first observed
using in vitro experiments. Monoubiquitination of histones was
reported but also polyubiquitination and subsequent degradation
of α-lactalbumin (Sung et al., 1991; Wing et al., 1992). UBE2B-
dependent ubiquitination was mainly performed using purified
Ubr1/E3α or cell extracts enriched in E3 ligase activity. Like other
E2 enzymes, the cellular context greatly influence the type of
ubiquitination so that we will mainly focus on the ubiquination
assays performed in skeletal muscle.
Using non-catabolic skeletal muscle extracts, Alfred Goldberg’s
laboratory found that UBE2B was a major actor of the so-called
N-end-rule pathway, i.e., the labeling and subsequent degra-
dation of proteins dependent on the N-terminal amino acid
of the degraded protein (Solomon et al., 1998a). Accordingly,
UBE2B and its isoform UBE2A were reported to represent nearly
half of total ubiquitin conjugation in skeletal muscle and other
cell types, underscoring the importance of the UBE2B family
(Rajapurohitam et al., 2002; Siepmann et al., 2003). Other studies
used muscle cell extracts from catabolic animals (diabetes, cancer,
and sepsis) and found that the N-end rule pathway (that includes
the enzymes UBE2B and Ubr1 mostly explained increased ubiq-
uitination rates (Solomon et al., 1998a; Lecker et al., 1999).
The use of a dominant negative UBE2B and inhibitors of Ubr1
confirmed this hypothesis and suggested that 60–80% of the ATP-
dependent degradation of soluble muscle proteins was mediated
by the N-end rule pathway (Solomon et al., 1998b). Accordingly,
hypoactivation of the UPS and low polyUb conjugate levels in
skeletal muscles were attributed to a repression of the N-end
rule pathway in thyroidectomized and hypophysectomized rats
(Solomon et al., 1998a). A tricky observation was that UBE2B
ubiquitinated model substrates like lysozyme or α-lactalbumin
but not the main contractile proteins actin and myosin (Solomon
et al., 1998b; Lecker et al., 1999) and that the impact of the
N-end rule pathway was only demonstrated in muscular solu-
ble extracts. However, different explanations may relativize this
absence of effect of UBE2B on the main contractile proteins. First,
the fact that UBE2B (and more globally the N-end rule path-
way) acts mainly on the soluble fraction from skeletal muscle
extracts does not exclude a role on contractile protein turnover.
Indeed, a fraction of these proteins are always present in such
cell extracts and may represent a transient rapidly evolving pool
(Neti et al., 2009). Second, a single E3 was used in ubiquitina-
tion assays and we know that E2s work with several partners in
cells. Finally, another aspect is the potential redundancy between
UBE2A and UBE2B but this point will be addressed in the last
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paragraph of this review. It seems very unlikely that a so abundant
E2 (UBE2B) would be restricted to a single E3 in skeletal mus-
cles since in other organs/cell types UBE2B interacts with the E3
ligases Rad18, Ubr2, Bre1, and Mdm2 for controlling histones,
p53, PCNA and myc proteins ubiquitination respectively (Gross-
Mesilaty et al., 1998; Kim et al., 2009; An et al., 2010; Hibbert
et al., 2011; Chen et al., 2012). Depending on the cognate E3,
UBE2B is implicated in different metabolic pathways from tran-
scriptional silencing during spermatogenesis (An et al., 2010) to
DNA repair (Hibbert et al., 2011). In skeletal muscle most studies
focused on Ubr1-UBE2B but the list of cognate E3s and the roles
of each UBE2B-E3 couples are probably far from being closed.
An important point when addressing the biochemical role
of E2 enzymes is to determine the kind of ubiquitin linkages
promoted. However, no study reported the type of Ub chain(s)
UBE2B promotes in skeletal muscle and we can only elaborate
hypotheses based on studies performed in other cell types. Like
other E2s, UBE2B is able to build different Ub chains depending
on the context and the ligase. In vitro assays performed without
any E3 ligase showed that UBE2B is able to promote K11, K48,
and K63 Ub chains (David et al., 2010). As underlined by the
authors, this kind of assay only shows the (minimum?) capac-
ity of E2 enzymes for building Ub chains. This was confirmed
for UBE2B, as pioneering studies showed that N-end rule sub-
strates were labeled with K48 chains when Ubr1 was used as an
E3 ligase (Chau et al., 1989). Likewise, UBE2B-dependent ubiq-
uitination of β-catenin was observed in breast tumor cells, which
was attributed to K63 Ub chain formation (Shekhar et al., 2008).
In the latter case, UBE2B did not promote protein degradation by
the 26S proteasome but rather enabled β-catenin to escape degra-
dation. K11 Ub chains were observed in vitro but clear data about
the implication of UBE2B for building these chains in vivo are
still lacking (Hibbert et al., 2011). PolyUb chain formation is not
the only signal UBE2B can promote, as its activity is restricted to
monoubiquitination of PCNA and histone H2B when combined
with the E3 ligases Rad18 and Bre1 respectively (Kim et al., 2009;
Hibbert et al., 2011).
In conclusion, Ub chain formation and the substrates targeted
by UBE2B in skeletal muscle are still a mystery and we still do not
know whether UBE2B is able to target myofibrillar proteins.
THE UBE2D FAMILY: THE FALSE FRIENDS?
Expression levels
The UBE2D/UBC4/UBC5/17 kDa-E2/UbcH5 family belongs to
class I E2 enzymes like UBE2B (Van Wijk and Timmers, 2010).
Like the UBE2B family, the UBE2D isoforms share high protein
homology ranging between 90 and 93% identity in humans and
most studies considered that they share common properties. This
is the second most studied family in skeletal muscle as UBE2D1
(UbcH5a), D2 (UbcH5b), and D3 (UbcH5c) are commonly used
for their ability to build Ub conjugates on substrates in vitro with
MuRF1 as an E3 ligase (Kedar et al., 2004; Clarke et al., 2007;
Fielitz et al., 2007; Polge et al., 2011). Indeed, in vitro assays using
UBE2Ds and MuRF1 allowed the polyubiquitination of the main
contractile proteins like actin, myosin heavy chain and troponin.
As MuRF1 is the major E3 ligase that targets myofibrillar proteins
for their degradation by the 26S proteasome, a tempting shortcut
is to associate UBE2D enzymes andmuscle atrophy. However, this
might not be so simple.
In rats submitted to Dex treatment, UBE2D2 mRNA lev-
els were enhanced together with other UPS components. By
contrast with the latter, UBE2D2 was insensitive to IGF-1 treat-
ment (Chrysis and Underwood, 1999). This lack of effect of
anabolic stimuli may be due to switches from different group
of targets using different E3 ligases but this remains to be clari-
fied. The most complete study about UBE2D was performed by
Alfred Goldberg’s laboratory that checked in rodents’ muscles the
expression levels of proteolytic genes in different catabolic sit-
uations, i.e., fasting, diabetes, chronic renal failure and cancer
(Lecker et al., 2004). UBE2D2 was chosen as representative of the
family, but was not up-regulated in any of the catabolic condi-
tions tested. This suggests that glucocorticoid treatment is one of
the few if not unique catabolic situation that induces an overex-
pression of UBE2D2. Other observations do not favor a role of
UBE2D in the muscle atrophying program (see below) and thus
caution should be taken when associatingMuRF1 and UBE2D for
identifying substrate targeting mechanisms in skeletal muscle.
Ubiquitination activity: E3 partners and substrates
UBE2Ds are very promiscuous enzymes that exhibit ubiquitina-
tion activity with a huge number of E3 ubiquitin ligases toward
various substrates. A good example of this wide interaction pat-
tern was provided by E2-E3 interaction screenings. Using 10
different E3 ligases (including the MuRF family: MuRF1, MuRF2
and MuRF3) and 11 different E2 enzymes, only the UBE2D fam-
ily (UBE2D2 and D3) was able to promote in vitro ubiquitination
with all the E3 ligases tested (Marblestone et al., 2013). Similarly,
only the UBE2D members tested (UBE2D1, D2, and D3) were
able to ubiquitinate myosin heavy chain in vitro with MuRF1 or
MuRF3 as cognate E3 ligases (Fielitz et al., 2007). Large screen-
ing using Yeast two-Hybrid (Y2H) assays lowered the percentage
of positive interactions between UBE2D and E3 ligases but this
family still remained in the top of E2-E3 interactions as they total-
ized 34–40% of all the detected interactions (Markson et al., 2009;
Van Wijk et al., 2009; Napolitano et al., 2011). Unfortunately, the
MuRF family was omitted in these wide screenings.
UBE2D enzymes lack specificity for chain linkage in vitro,
although they exhibit a preference for building K11, K48, and
K63 chains (Kim et al., 2007; Ye and Rape, 2009). UBE2Ds gener-
ally also exhibit low specificity toward E3 enzymes and substrates
when used in vitro (Brzovic et al., 2006; Wenzel et al., 2011b).
These authors suggested that this due to peculiar Ub binding on
the backside region of UBE2D. It is believed that the backside face
of UBE2 enzymes opposite to the catalytic pocket does not par-
ticipate to the covalent Ub attachment to the substrate. In fact,
the use of the backside region extends to ubiquitin-like modifi-
cations as UBE2I, the SUMO-specific E2, binds SUMO through
the backside region for promoting sumoylation (Knipscheer et al.,
2007). Ub binding through the backside of UBE2D (and some
other E2s) ended up with a proposed mechanism in which Ub
bound to the back face of UBE2D elicits an aggregation of UBE2D
enzymes that promotes a highly efficient processive ubiquiti-
nation mechanism (Ye and Rape, 2009). Such an aggregation
of UBE2D enzyme may be responsible for the high efficacy of
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UBE2D2 within in vitro ubiquitination assays whatever the E3
and the substrate. If true, this raises the question of the physio-
logical relevance of MuRF1-UBE2D ubiquitination assays, not for
the recognition of the substrate that belongs toMuRF1 but for the
kind of chains built on substrates and the role of UBE2D enzymes
in atrophying skeletal muscle. Altogether, the UBE2D family is
far from being a pretender for playing an important role during
skeletal muscle atrophy in view of the available data.
OTHER UBE2s
Few other studies addressed the remaining E2 enzymes in atro-
phying skeletal muscles. A single study screened for several E2
enzymes and found that UBE2G1 was up-regulated in skeletal
muscles from rodents undergoing chronic renal failure (CRF),
diabetes, fasting, and cancer (Lecker et al., 2004). The second iso-
form of the family (UBE2G2) was also up-regulated in CRF and
cancer animals while UBE2L3 and UBE2O were enhanced only
during fasting. UBE2L3 was also up-regulated during immobi-
lization in pigs (Banduseela et al., 2009) and denervation induced
an increased expression of UBE2O in the gastrocnemius mus-
cle from mice (Gomes et al., 2012). It should be noticed that
UBE2O was formerly depicted as predominantly expressed in
skeletal muscle and heart (Yokota et al., 2001), but this was
due to erroneously loaded commercial blots as this enzyme is
highly expressed in other organs. Indeed, UBE2O is abundant in
bones (NextBio body Atlas https://www.nextbio.com) and plays
an important role in osteoblast formation (Hao et al., 2013;
Zhang et al., 2013). In fact, UBE2O overexpression in C2C12
skeletal muscle cells induces an osteoblastic program and this E2
is thus a poor candidate for playing a role during skeletal muscle
atrophy. UBE2H is implicated in the negative control of the IGF-
1 and insulin-signaling pathway with the E3 ligase MG53/Trim72
during myogenesis in cultured C2C12 cells and in mice (Yi et al.,
2013; Nguyen et al., 2014b). However, the implication of UBE2H
in atrophying conditions has not been reported yet. UBE2J1 was
up-regulated in chronic renal failure (CRF), diabetes, fasting, can-
cer and immobilization (Lecker et al., 2004; Banduseela et al.,
2009), suggesting a recurrent role of this E2 in the atrophying pro-
cess. However, UBE2J1 (and its isoform UBE2J2) is a membrane
protein present in the endoplasmic reticulum (ER) (Oh et al.,
2006), which thus makes it a poor candidate for the targeting
of the contractile apparatus. Indeed, this E2 enzyme is a tail-
anchored protein facing the cytoplasm and is probably involved in
the ubiquitination ofmisfolded ormisassembled proteins. Finally,
UBE2V2 was up-regulated during spaceflight (Allen et al., 2009).
In summary, very few studies attempted to address the role
of E2 enzymes in skeletal muscle during atrophying processes.
A clear picture of the E2s up-regulated in different catabolic
conditions would be a first step. It is clear thatmost E2-E3 interac-
tions are weak and/or transient, which renders more difficult the
detection of E2-E3 couples. However, Y2H, SPR or Fluorescence
Resonance Energy Transfer (FRET) technologies should prove
to be useful tools (and already proved to be in non-muscle
cells) for tracking relevant interactions. Using knockdown and
overexpression approaches should also be valuable for address-
ing the physiological targets of E2 enzymes. The picture at that
time is kind of a black box and we do not know which E2(s)
is(are) important/implicated in skeletal muscle atrophy, which
E3 enzymes are working with them and what are their respective
targets.
SPECIFIC FEATURES OF E2 ENZYMES AND PITFALLS
Information about ubiquitination processes come from struc-
tures of E2-E3 couples identified in non-muscle cells but these
data are highly valuable for future studies addressing ubiqui-
tination specificity and role in the atrophying skeletal muscle.
Dissecting all the knowledge about E2-E3 structures is beyond the
scope of this review and readers are redirected to excellent reviews
(Ye and Rape, 2009; Van Wijk and Timmers, 2010; Wenzel et al.,
2011b). We will discuss the main features that should be taken
into account when studying ubiquitination in skeletal muscle.
STRUCTURE AND UBIQUITINATION SPECIFICITY
With the exception of UBE2O (230 kDa), E2 enzymes are rela-
tively small proteins, as class I E2s possessing only the catalytic
core (or Ubc fold) are within the 14–20 kDa range. Even E2
enzymes harboring N and/or C-terminal extension like UBE2U
barely exceed 35 kDa. The Ubc fold has a globular shape and con-
centrates all the necessary interaction surfaces for achieving Ub
conjugation (VanWijk and Timmers, 2010; Wenzel et al., 2011b).
Indeed, and despite their small sizes, each E2 interacts with vari-
ous proteins, and interacting partners are not restricted to E1, E3
ligases and ubiquitin. Indeed, a wide Y2H screen found that less
than one third of the interactions with E2 enzymes belong to E3
ligases, which means other partners may be part of the E2 net-
work (Markson et al., 2009). The multitude of interactions means
that E2 enzymes have developed a highly rationalized structure
that uses a limited number of residues for achieving a functional
role (VanWijk and Timmers, 2010; Wenzel et al., 2011b). In addi-
tion, the small number of E2 enzymes toward the vast number
of E3s has pushed cells to develop highly specialized overlap-
ping interaction domains so that each E2 interacts with a panel
of E3 ligases. However, other E2s like UBE2K lack a single Phe
residue crucial for E2 interaction with HECT-E3s (Homologs to
the E6-AP Carboxyl Terminus E3) thus suggesting a specialization
of some E2s (Huang et al., 1999). This model well illustrates the
importance of a single amino acid residue in E2 roles, as the intro-
duction of the crucial Phe in UBE2K allows the partial recovery
of a UBE2D mutant that lacked E2-HECT function (Nuber and
Scheffner, 1999).
Peculiar features of E2 interaction surfaces include overlap-
ping binding sites for E1 and E3s and a limited number of
crucial residues involved for each individual interaction. Three E2
regions aremainly involved in E1/E3 interactions namely the helix
1 (H1), and loops 4 and 7 (L4 and L7). The solved E2-E3 struc-
tures showed that a limited number of residues present in H1 and
one or two residues in each loop are important for E2-E3 interac-
tions (Wenzel et al., 2011b). This means that a modest number of
residues govern the choice of the E3 and that small modifications
on E2s modify the specificity toward E3s. For example a single
mutation of Ala96 to Asp disrupts BRCA1-UBE2D3 interaction
(Christensen et al., 2007). In addition, crucial residues for a given
E2 family can be unimportant for another one, which means
we can hardly predict interaction features for E2-E3 couples
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with unsolved structures. In addition to these canonical binding
regions, the E2 backside seems also to play an important role for
some E2-E3 interactions, e.g., UBE2G2 and the E3 ligase gp78
(Das et al., 2009; Randles and Walters, 2012). The G2BR domain
of gp78 specifically binds the backside region of UBE2G2 with
high affinity only when the E2 is charged with Ub, while it exhibits
low affinity toward the uncharged UBE2G2. This mechanism is
at the basis of processive ubiquitination. Clearly, some E3 ligases
can interact with the backside region of E2 enzymes (see UBE2B-
Rad18 structure, Figure 1) by using non-RING domains, which
either enhances or inhibits processive Ub chain formation (Bailly
et al., 1997; Brzovic et al., 2006; Chen et al., 2006; Notenboom
et al., 2007; Das et al., 2009; Hibbert et al., 2011; Metzger et al.,
2013; Nguyen et al., 2014a). For example, depending on the E2-E3
couples, interaction of E3 to the backside either favors monoubiq-
uitination (UBE2B-Rad18, UBE2E3-AO7) or polyubiquitination
(UBE2G2-gp78) underscoring the variety of modulation E2-E3
couples have developed for achieving Ub chain formation. As the
backside region is probably a multifunctional binding surface,
future studies may uncover other interactors/binding residues
that may be related to different physiological functions.
Some E2 enzymes like the UBE2D family have the ability to
build Ub conjugates in vitro without the help of E3 ligase, but E3
ligases are clearly needed for the orientation of the substrate and
serves as scaffolds for positioning correctly the E2 and the target
for optimal Ub transfer on the dedicated lysine residue (Huang
et al., 1999; Zheng et al., 2000). Correct positioning is not the
only reason for cells to develop a “quality control” mechanism
using E3 ligases. Indeed, E2-Ub reactive species may be deleteri-
ous for cellular metabolism. A common feature for ubiquitination
is the conformation modification sustained by E3 ligases. E2-
Ub possess a flexible structure in which each protein is relatively
independent while the RING finger of E3 ligases imposes a close
structure that carefully orients Ub for achieving a highly spe-
cific ubiquitination of defined residues with the desired Ub chain
(Dou et al., 2012; Pruneda et al., 2012; Soss et al., 2013; Berndsen
and Wolberger, 2014). UBE2V-UBE2N heterodimer developed
self-control ubiquitination mode and correctly orientates K63 for
Ub chain formation onto the substrate. Indeed, UBE2V lacks cat-
alytic activity but positions Ub between the V-N heterodimer,
which brings Ub in front of the RING and allows ubiquitination
by UBE2N. However, the presence of a minimal RING domain
is necessary for optimal activity (Eddins et al., 2006; Yin et al.,
2009). Another way for cells to control the ubiquitination process
is to use a single E2 enzyme that lacks reactivity against lysine,
i.e., it can not build chains even though it is able to interact
with RING finger E3 ligases. UBE2L3 is believed to lack intrinsic
Ub chain building ability and works primarily with HECT E3 or
with RING-between-RING (RBR) ligases (Wenzel et al., 2011a).
In another example of controlled ubiquitination by an E3 ligase,
the role UBE2E3 alone was largely restricted to monoubiquiti-
nation while the presence of its cognate RING finger E3 ligase
FIGURE 1 | Crystallographic structure of human UBE2B. (A) Alignment
of mammalian UBE2A and UBE2B. Consensus sequence (red bar) is
shown at the top and differential residues are highlighted in green. (B)
UBE2B structure backside view (PDB code 2YBF). Specific residues within
UBE2B are shown in yellow. (C) The E2 binding domain of the E3 ligase
Rad18 (shown in blue) covers the central area of UBE2B backside,
including some of the specific residues (yellow) that are different between
UBE2B and UBE2A.
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RNF25 greatly increased polyUb formation, thereby limiting E2
ubiquitination activity in absence of an E3 (Nguyen et al., 2014a).
The catalytic cysteine and the surrounding HPN residues form
the active site of E2 enzymes but are not always sufficient to
explain the ubiquitination mechanism on protein substrates. For
example, UBE2G2 possesses acidic residues in flexible loops com-
pleting the HPN residues and the binding of Ub or E3 onto
UBE2G2 seems a prerequisite for a more ordered structure and
thus for efficient ubiquitination activity (Ju et al., 2010). This
means that Ub or one of the cognate E3 might be necessary for
detecting Ub conjugation in vitro. It is tempting to extrapolate
that other E2 enzymes need E2-Ub, specific E2-E3 configuration
or a third-party protein for correctly ordering the catalytic site. If
true, this may explain why so few E2-E3 couples are active in vitro
(Wenzel et al., 2011b). For UBE2Ds, the absence of such acidic
residues favors constitutive ubiquitination activity, which could
explain the remarkable in vitro activity of these E2s (Kim et al.,
2007; Marblestone et al., 2013).
The role of the N or C-terminal extensions present in some E2
enzymes is far from being understood. The UBE2J family uses the
C-terminal extension for anchoring to the ER membrane, which
specializes UBE2J1 and J2 to ER-linked ubiquitination activity
(Oh et al., 2006; Van De Weijer et al., 2014). UBE2C N-terminal
extension plays a role in the ubiquitination mechanism both at
the ubiquitination and target lysine levels (Summers et al., 2008)
while UBE2R2 C-terminal extension may be implicated in both
ubiquitination and localization (Sadowski et al., 2007). The large
UBE2O is per se a combined E2-E3 entity (Berleth and Pickart,
1996) but it is also able to work with the E3 MAGE-L2/TRIM27,
suggesting multi-functional roles for this E2 (Hao et al., 2013).
More than half of the E2 enzymes exhibit extensions and future
studies will have to clearly identify their roles, which may encom-
pass localization, recognition of substrates, binding with specific
E3s, modulation of activity, etc.
The above examples highlight that the Ubc fold of E2 is a com-
pact economical structure that optimizes each contact surface. A
single amino acid modification, the presence of a substrate/co-
factor/specific E3 can greatly modify the E2 activity. This under-
scores huge constraints not always compatible with in vitro assays.
Not all surfaces and crucial residues have been discovered yet and
future studies will probably highlight new interaction with yet
unknown partners (as suggested by Y2H screens) that will help
for better defining E2 roles.
E2 EXPRESSION LEVELS
Some E3 ligases exhibit a restricted expression; this is the case
for the MuRF family and MAFbx whose expression is limited to
skeletal, cardiac, and smooth muscles (Bodine et al., 2001; Bdolah
et al., 2007; Yoshida et al., 2010; Bodine and Baehr, 2014). For
E2 enzymes, the relatively small number of enzymes makes it
almost impossible that a given E2 could be restricted to a sin-
gle organ. However, E2 enzymes can be highly present or not
detectable, which means that some restriction of expression exists
and depends of the cell type/organ studied (Uhleìn et al., 2015).
Data base like NextBio body Atlas (https://www.nextbio.com)
may give a general picture of the expression levels of E2 enzymes.
For example, only 26 E2 enzymes were detected in NIH3T3 cells
both at the mRNA and protein levels (Schwanhausser et al., 2011,
2013). Similarly, important discrepancies in E2 abundance were
detected between E2 enzymes in both Hela cells with ratio >200
for UBE2L3/UBE2T for example (Schwanhausser et al., 2011,
2013). Similarly, other authors found 50 times more UBE2B than
UBE2D in the rat gastrocnemius muscle while similar levels of
these enzymes were observed in the brain (Rajapurohitam et al.,
2002). Interestingly, the much higher proportion of UBE2B over
UBE2D in skeletal muscle reflected a very low abundance of
UBE2D. In skeletal muscle, UBE2A and UBE2B represent a fair
amount of total ubiquitination but other E2s like UBE2E1, G1,
G2, H, J1, J2, L3, N, O, V1, V2, and Z are also well represented
in this tissue. By contrast, others like UBE2C, K, Q1, and Q2 are
quite absent or present at low levels, which brings the question of
the heterogeneity of the tissue. Indeed, UBE2K is highly abundant
in peripheral blood cells and the low levels of UBE2K detected in
skeletal muscle may reflect the presence of multiple cell types in
the tissue rather than “true” presence of UBE2K in skeletal muscle
cells. Using cell culture may be an alternative but keeping in mind
that myotubes are not fully differentiated muscles. Importantly,
the presence of an E2 enzyme in the organ studied is a first step
when studying E2-E3 interactions in vitro for being sure that the
enzymes have a chance to interact in vivo.
Unfortunately, few studies have addressed the expression levels
of E2 enzymes in the different tissues/organs, including skeletal
muscle. However, we can hypothesize that the observed varia-
tions are probably correlated with the presence of cognate E3s, the
substrates and ultimately the physiological roles of E2 enzymes.
INTERACTIONWITH SUBSTRATES
When considering the Ubc fold, contacts between the E2 enzymes
and the substrates they ubiquitinate is limited to the strict mini-
mum. This is a peculiar mode of action due to the scaffold role
of E3 enzymes. This means that even though E2 enzymes gen-
erally retain the catalytic role during the ubiquitination process
they do not have any intrinsic affinity for their target. However,
E2 extensions may play substrate-binding role and complete the
pleiotropic capacity of E2 enzymes. This is the case for UBE2C,
one of the Anaphase Promoting Complex (APC) E2 enzymes,
that combines E2-E3 capacities thanks to its N-terminal exten-
sion (Summers et al., 2008). However, this is more an exception
than the rule. Therefore, classical approaches like pulldown assays
are useless for identifying the physiological targets of E2s, thus
increasing the difficulty for such identifications. In addition, E2-
E3 interactions are per se generally weak and transient, which urge
the development of new approaches for elucidating the physiolog-
ical role of each E2 enzyme. In a recent work, fused E2-E3 con-
structions were used for identifying new targets of the Mulan E3
ligase (Ambivero et al., 2014). The authors first identified Mulan
E2 interactors using Y2H assays and then fused the RING-finger
domain of Mulan to the identified E2s. The Mulan RING-finger-
E2 fusion proteins were then used as bait for identifying new
Mulan targets. This interesting approach may be used with other
fusion strategies like E3-substrate to identify specific E2s.
POSTTRANSLATIONAL MODIFICATIONS
Metabolic pathways are widely regulated through posttrans-
lational modifications, ubiquitination being one of them.
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Phosphorylation is commonly used formodulating enzyme activ-
ity and E2 enzyme activity can also be modulated by phos-
phorylation. Few studies have addressed this point but a good
example comes from UBE2B-UBE2A phosphorylation (Sarcevic
et al., 2002; Kumar et al., 2010). Phosphorylation of a single
residue of UBE2B (Ser120) was shown to control the activity of
this E2 enzyme. Indeed, the unphosphorylated form of UBE2B
drives K48 polyUb targeting of model N-end rule substrates using
the E3 Ubr1, whereas a phospho-mimic UBE2B was restricted to
mono-ubiquitination (Kumar et al., 2010). This was confirmed by
the abolition of histone mono-ubiquitination in Ser120-mutated
UBE2A (Sarcevic et al., 2002). Interestingly, the Ser120 residue
is positioned close to the catalytic Cys and Ser120Ala muta-
tion abolished UBE2B activity, suggesting that this residue has
a pivotal role for ubiquitination. This mechanism is not com-
mon to all E2 enzymes, as the paralogous residue in UBE2D
exhibits no importance for ubiquitination activity (Kumar et al.,
2010). Based on protein sequence, the authors predicted poten-
tial phosphorylation sites in the Ubc fold of UBE2C, UBE2G1,
and UBE2R1. Phosphorylation was also observed in the acidic
tail of UBE2R1 and increased ubiquitination activity followed
by accelerated cell cycle in yeast (Sadowski et al., 2007; Coccetti
et al., 2008). Phosphorylation-linked ubiquitination control was
also suggested for UBE2J1. However, phosphorylation state did
not affect stability, localization or E3 binding with the cognate E3
Parkin (Oh et al., 2006).
We can hypothesize that other E2 enzymes may be modified by
phosphorylation (or other posttranslational modifications) and
thus diversify the ubiquitination roles of these enzymes. More
generally, if posttranslational modifications prove to be more
common within E2s, this will virtually expand the number of E2
enzymes present in cells.
IN VITRO UBIQUITINATION ASSAYS: INTERPRETATION AND
USEFULNESS
In vitro ubiquitination assays are widely used in the UPS world
and they proved to be useful for deciphering the mechanism of
ubiquitination, e.g., for determining the residues in E2 and E3
enzymes that are crucial for sustaining an efficient catalytic activ-
ity. They have been also widely used for suggesting that a target
protein was the physiological substrate of an E3 ligase. However,
ubiquitination assays usefulness is questionable for identifying
the right E2 enzyme. A typical case is UBE2D, a promiscuous
E2 enzyme that exhibits an incredible ability for Ub conjugation
in vitro. This is detrimental as it is almost impossible to discern
physiologically relevant and non-relevant activity. As discussed
before, UBE2D builds in vitro different types of Ub chains on
muscle-specific proteins in association with MuRF1 or MuRF3
(Kedar et al., 2004; Clarke et al., 2007; Fielitz et al., 2007; Polge
et al., 2011). This brings the question of specificity since the type
of Ub chains define the fate of the substrate, and it is astonish-
ing that cells can deal with an E2 not able to bring specificity
(Kim et al., 2007; Ye and Rape, 2009). Combined with our data,
the simplest explanation is that the former ligases are not in vivo
partners of UBE2D and that the intrinsic capacity of UBE2D
to non-specifically form Ub conjugates in vitro was the main
determinant. In addition, UBE2D may be involved in a more
complicated way in the ubiquitination process. It has been shown
that E2s can work in concert, which means that cooperation
between at least two different E2 enzymes influences the ubiq-
uitination process. This is the case for UBE2W and UBE2E2,
this dimer initiating Ub chain initiation when combined with
the E3 ligase BRCA1 and UBE2N-UBE2V1 dimer elongating Ub
chains (Christensen et al., 2007). Similarly, UBE2D was proposed
to only initiate ubiquitination and other E2 enzymes might be
responsible for the development of Ub chains, which is the case
for UBE2D-UBE2K ubiquitination activity within the APC com-
plex (Rodrigo-Brenni and Morgan, 2007; Ye and Rape, 2009). E2
combinations represent thus a possibility of control of Ub chain
formation by cells, together with posttranslational modifications
and binding with other partners. These parameters are often diffi-
cult to take into account in vitro and, as a first step, more sensitive
approaches should be favored and combined when addressing
E2-E3 interactions.
E2-E3 INTERACTION SCREENING
Few E2-E3 interactions are detectable using classical pulldown
assays, with some exceptions like UBE2Bwith the E3 ligase Rad18.
The reason for such transient interaction is adaptive and allows
highly processive ubiquitination of a substrate. This is well illus-
trated by the ubiquitination process of UBE2G2 and the RING
E3 gp78 (Das et al., 2013). Binding of UBE2G2 to the dedicated
domain G2BR on gp78 increases UBE2G2-RING binding affin-
ity and promotes ubiquitination of the substrate. Concurrently,
Ub discharge lowers the UBE2G2 affinity for G2BR and UBE2G2
is released rapidly for being used in the next round of ubiqui-
tination. This example highlights also the potential role of Ub
charging on E2 for achieving efficient binding on the cognate
E3. Similarly, when they are charged with Ub some E2 enzymes
exhibit enhanced affinity for co-factors such as Ub Binding
Domains (UBD) or membrane receptors (Hoeller et al., 2007;
Ravid and Hochstrasser, 2007). This is the case for the yeast
homolog of UBE2G2 that binds to Cue1 at the ER membrane,
which localizes both ubiquitination activity and specificity toward
the target proteins. Thus, while most available data suggest that
E2-E3 interaction is generally stand-alone, this might not be a
ubiquitous feature. Depending on the E2-E3 couples studied, the
presence of binding partners andUbmay influence the affinity for
a given E2 to cognate E3 ligases. This may partly explain why Y2H
screens failed to find any E2 for some E3s and vice versa (Markson
et al., 2009; Napolitano et al., 2011) and also why the two-third of
the interactions observed for E2s in Y2H assays were not belong-
ing to E3s (Markson et al., 2009). This aspect should also be taken
into account in future experiments.
DOES FAMILY MEANS REDUNDANT FUNCTIONS?
Some families of E2 enzymes exhibit highly similar isoforms. This
is the case for UBE2A and UBE2B that share 96% identity at the
protein level (Figure 1A), the UBE2D family (90–93%), UBE2E
(80–85%), UBE2Q (72%), UBE2R (79%), and UBE2V (88%).
These close isoforms are often considered as possessing redun-
dant functional activities. In skeletal muscle, UBE2B knockout
was inefficient for improving muscle mass in starved animals
and the authors concluded that UBE2A activity was sufficient
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to compensate for UBE2B loss (Adegoke et al., 2002). By con-
trast, the very same E2 enzymes exhibited clear differential role
in testis as UBE2B knockout induced male infertility (Roest et al.,
1996). The reasons for such discrepancies are not clear but knock-
out often induces differential compensation phenomena due to
long-term absence of a protein during all the development of
the animal. An alternative explanation may also be that the E3
“arsenal” is different between testis and skeletal muscle. A first
clue is the highly conserved sequence for each enzyme among
species. There is no amino acid difference for mammalian UBE2B
and only a conservative Val/Ile modification between human and
Chinese turtle for example. As discussed above, a single amino
acid modification within the Ubc fold can change the affinity
toward E3s and the ubiquitination activity, suggesting that the
seven different amino acids between UBE2A and UBE2B reflect
functional differences. UBE2B structure gives another indication
as six out of the seven residues form two patches located in the
backside of UBE2B (Figure 1B). This region possesses at least
two potential functions, non-covalent binding of Ub and interac-
tion with E3 ligases. These residues being solvent exposed, we can
hypothesize that they may have some impact in forming interac-
tions either with E3 ligases or with other partners. Accordingly,
the crystallographic structure of human UBE2B with the E2-
binding domain of the cognate E3 ligase Rad18 shows that the
differential amino acids are at the interface of the two proteins
(Figure 1B).
Available information is in favor of at least partially distinct
functions in vivo but robust data are clearly needed for clarify-
ing whether close isoforms should be considered as distinct E2
enzymes sharing common properties with their counterparts or
whether they are only spare wheels.
FUTURE DIRECTIONS
This review shows that our knowledge on E2 enzymes in skele-
tal muscle is very fragmentary, mostly because E3 ligases have
been preferentially studied. We now know that E2 enzymes are
crucial for the fate of individual substrates and are implicated in
major functions like spermatogenesis, mitophagy or the devel-
opment of pathologies (e.g., cancer). These examples highlight
the potential that E2s represent for the future development of
therapeutic strategies and underscore the lacks we have in this
area. Future studies should decipher the mechanisms involved in
substrate ubiquitination in skeletal muscle, keeping in mind that
E2-E3-partners-substrates heteromers represent the active entity
in vivo and that each individual switch within the heteromer
may uncover a different mechanism. We can take advantage from
other studies to characterize the regulation of muscular enzymes.
However, it is hard to predict which of the numerous strategies
already described in other cell types/organs will apply for deci-
phering the precise role of muscle ubiquitinating enzymes and
uncovering the contractile proteins they target.
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